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yale.edu).Donor T cell-mediated graft-versus-leukemia
(GVL) is the most effective and widely applied form
of adoptive immunotherapy against cancer. However,
even though the alloimmune effect of donor T cells
has been recognized in human allogeneic stem cell
transplantation (alloSCT) for decades, 2 limitations
onGVL are essentially unchanged: (1) GVL is difficult
to separate from graft-versus-host disease (GVHD),
and (2) many types of malignancies are GVL resistant
even when GVHDhas been induced. To better under-
stand GVL resistance we sought mouse models of
GVL-sensitive and GVL-resistant leukemias that
share genetic etiology and phenotype with their
human equivalents, and that can be created in different
mouse strains, including those that are gene-deficient.
Mouse chronic phase chronic myelogenous leukemia
(mCP-CML) is induced by retroviral transduction of
bone marrow cells with the human bcr-abl cDNA
(p210), and is characterized by a high white blood
cell count and splenomegaly with hematopoiesis dom-
inated by maturing myeloid and erythroid cells. If
p210 is cointroduced with the fusion cDNA from the
NUP98/HOXA9 translocation (found in de novo
AML and blast crisis CML), a leukemia dominated
by CD341 myeloblasts results (mouse blast crisis
CML; mBC-CML). Importantly for our studies,
mCP-CML is GVL sensitive, whereas mBC-CML is
relatively GVL resistant. We have created gene-defi-
cient mCP-CML andmBC-CML and combined these4with gene-deficient T cell donors, bone marrow do-
nors, and recipients to dissect mechanisms of GVL.
Although our comparative data set is not yet complete,
thus far, the basic mechanisms of immunogenicity are
shared by both leukemias: (1) cognate interactions
with donor T cells are required (ie, MHCI- or
MHCII-deficient leukemias are insensitive to CD8-
and CD4-mediated GVL, respectively); (2) impair-
ment of single cytolytic mechanisms does not effect
GVL (including perforin, FasL, TNF-a, and TRAIL),
which makes it unlikely that reduced surface expres-
sion of a single death receptor explains GVL resis-
tance; (3) host APCs are required for both CD4- and
CD8-mediated GVL (against mBC-CML); (4) donor
APCs are not required for CD8-mediated GVL; (5)
minorH antigen expression bymCP-CML and poten-
tial leukemia-specific tumor antigens are insufficient.
We are currently using leukemias deficient in PDL1,
PDL2, or TGF-b to examine potential inhibitory
pathways and leukemias deficient in ICAM-1 to inves-
tigate mechanisms of adhesion to T cells. To better
understand GVL resistance we have begun work to
identify subpopulations of mCP-CML and mBC-
CML enriched for leukemia stem cells, which we hy-
pothesize should be the most important GVL targets.
A detailed characterization of these leukemia stem cells
should facilitate the identification of mechanisms
underlying GVL resistance and thereby provide new
targets to augment GVL.
